SECsense Logo

Nukkleus Inc. 8-K Filing: Key Insights on Common Stock & Warrants (Dec 2024)

$NUKK
Form 8-K
Filed on: 2024-12-17
Source
Nukkleus Inc. 8-K Filing: Key Insights on Common Stock & Warrants (Dec 2024)

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Company Identification: The company referenced in the report is Nukkleus Inc., identified by the SEC Central Index Key (CIK) number 0001787518.
  2. Report Type and Date: The document is an 8-K filing dated December 15, 2024. An 8-K is typically used to report major events that shareholders should be aware of.
  3. Common Stock Details:
  • The par value of the common stock is $0.0001 per share.
  • The stock is traded on NASDAQ under the ticker symbol "NUKK".
  1. Warrants Information:
  • The company has issued warrants, with each warrant exercisable for one share of common stock at a price of $11.50 per share.
  • These warrants are listed on NASDAQ under the ticker symbol "NUKKW".
  1. Contact Information: The company's headquarters is located at 525 Washington Blvd., Jersey City, NJ 07310. The contact phone number is 212-791-4663.
  2. Financial Reporting Context: The report uses the XBRL (eXtensible Business Reporting Language) format, which indicates that it is prepared for electronic filing with the SEC and is structured for better data analysis.
  3. Units of Measure: The financial information is presented using standard measures:
  • Currency is denominated in USD.
  • Shares are the unit of equity measurement.
  1. Regulatory Compliance: The report adheres to US GAAP standards, indicating compliance with generally accepted accounting principles in the United States.

Insights:

  • The presence of both common stock and warrants suggests that the company is engaging in capital-raising activities, potentially to fund growth initiatives or operations.
  • The low par value of common stock may indicate that the company is in a stage where it is leveraging equity financing for expansion or operational needs.
  • The exercise price of the warrants at $11.50 could be seen as a strategic price point, possibly reflecting the company's valuation expectations.

This report provides an overview of key equity instruments of Nukkleus Inc. and indicates that the company is actively managing its capital structure through the issuance of both common stock and warrants.